O
Ola Weiland
Researcher at Karolinska University Hospital
Publications - 261
Citations - 14370
Ola Weiland is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Hepatitis C virus & Ribavirin. The author has an hindex of 55, co-authored 260 publications receiving 13877 citations. Previous affiliations of Ola Weiland include Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
Telaprevir for retreatment of HCV infection.
Stefan Zeuzem,Pietro Andreone,Stanislas Pol,Eric Lawitz,Moisés Diago,Stuart K. Roberts,R. Focaccia,Zobair M. Younossi,Graham R. Foster,Andrzej Horban,Peter Ferenci,Frederik Nevens,Beat Müllhaupt,Paul J. Pockros,R. Terg,Daniel Shouval,Bart van Hoek,Ola Weiland,Rolf van Heeswijk,Sandra De Meyer,Don Luo,G. Boogaerts,Ramon Polo,Gaston Picchio,Maria Beumont +24 more
TL;DR: Telaprevir combined with peginterferon plus ribavirin significantly improved rates of sustained virologic response in patients with previously treated HCV infection, regardless of whether there was a lead-in phase.
Journal ArticleDOI
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Jordan J. Feld,Kris V. Kowdley,Eoin Coakley,Samuel H. Sigal,David R. Nelson,Darrell H. G. Crawford,Ola Weiland,Humberto Aguilar,Junyuan Xiong,Tami Pilot-Matias,Barbara DaSilva-Tillmann,Lois Larsen,Thomas Podsadecki,B. Bernstein +13 more
TL;DR: In previously untreated patients with HCV genotype 1 infection and no cirrhosis, a 12-week multitargeted regimen of ABT-450/r-ombitasvir and dasabuvir with ribavirin was highly effective and was associated with a low rate of treatment discontinuation.
Journal ArticleDOI
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem,Geoffrey Dusheiko,Riina Salupere,Alessandra Mangia,Robert Flisiak,Robert H. Hyland,Ari Illeperuma,Evguenia S. Svarovskaia,D.M. Brainard,William T. Symonds,G. Mani Subramanian,John G. McHutchison,Ola Weiland,Hendrik W. Reesink,Peter Ferenci,Christophe Hézode,Rafael Esteban +16 more
TL;DR: Therapy with sofosbuvir-ribavirin for 12 weeks in patients with hepatitis C virus genotype 2 infection and for 24 weeks in Patients with HCV genotype 3 infection resulted in high rates of sustained virologic response.
Journal ArticleDOI
Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
Olle Reichard,Gunnar Norkrans,Aril Frydén,Jean-Henrik Braconier,Anders Sönnerborg,Ola Weiland +5 more
TL;DR: It is suggested that patients with high HCV-RNA loads should be treated with interferon α-2b and ribavirin.
Journal ArticleDOI
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
Stefan Zeuzem,Maria Buti,Peter Ferenci,Jan Sperl,Yves Horsmans,Janusz Cianciara,Endre Ibranyi,Ola Weiland,Stephanie Noviello,Clifford A. Brass,Janice K. Albrecht +10 more
TL;DR: Investigating this schedule in the era of pegylated interferon-alpha plus ribavirin for chronically infected patients with a low baseline HCV-RNA concentration found it may be treated for 24 weeks without compromising sustained virologic response rates.